Compare · LLY vs MLYS
LLY vs MLYS
Side-by-side comparison of Eli Lilly and Company (LLY) and Mineralys Therapeutics Inc. (MLYS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MLYS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.13T, about 511.2x MLYS ($2.20B).
- Over the past year, LLY is up 48.0% and MLYS is up 96.4% - MLYS leads by 48.4 points.
- MLYS has been more active in the news (12 items in the past 4 weeks vs 11 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 10 for MLYS).
- Company
- Eli Lilly and Company
- Mineralys Therapeutics Inc.
- Price
- $1196.14+0.89%
- $26.73-0.98%
- Market cap
- $1.13T
- $2.20B
- 1M return
- +7.05%
- +3.69%
- 1Y return
- +48.02%
- +96.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 11
- 12
- Recent ratings
- 25
- 10
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Latest MLYS
- Chief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $199,885 worth of shares (7,438 units at $26.87) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Medical Officer Rodman David Malcom sold $11,036 worth of shares (416 units at $26.53) as part of a pre-agreed trading plan and exercised 416 shares at a strike of $15.44 (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 units (SEC Form 4)
- Chief Medical Officer Rodman David Malcom exercised 14,058 shares at a strike of $7.28 and sold $556,671 worth of shares (20,407 units at $27.28) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 51,384 units (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Amendment: SEC Form 144/A filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.